A molecular analysis of PGE receptor (EP) expression on normal and transformed B lymphocytes: Coexpression of EP1, EP2, EP and EP4

Eric R. Fedyk, John M. Ripper, Deborah M. Brown, Richard P. Phipps

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The E-series prostaglandins (PGEs) are complex lipid regulators of B lymphocyte function. They inhibit the growth of certain B lymphoma lines. We report that heterogeneity with respect to PGE-induced growth inhibition correlates with the maturation state of the B cell lines. Specifically, the pre-B cell line 70Z/3 and the immature lymphoma CH31 are extremely sensitive to PGE2. To a lesser degree, other immature lymphomas (CH33, ECH408.1 and WEHI-231) are sensitive to PGE2. More mature lymphomas (BAL-17, CH12 and CH27) and fully differentiated myelomas (J558 and MOPC-315) are insensitive to PGE2. It is unknown what subtype of PGE receptor(s) (EPs) are expressed by B lymphocytes. It is also unknown if modulation of EP receptor expression could account for the differences in the sensitivity of these B cell lines to PGE2. To investigate these issues, reverse transcriptase polymerase chain reaction, Northern blot and DNA sequencing analyses were employed to obtain a definitive EP receptor subtype profile for these B cell lines, and for normal splenic B lymphocytes. Both normal and transformed B lymphocytes express mRNA encoding EP1, EP and EP4 subtypes of PGE receptors. The B lineage cells do not express EP nor EP mRNA. The B cell lines are clonal, indicating that EP1, EP and EP4 mRNA are coexpressed. Surprisingly, quantitative differences in basal EP1, EP and EP4 expression were not observed between B cell lines despite their differing susceptibilities to PGE-induced growth inhibition. Conversely, the polyclonal activator LPS selectively upregulates EP4 mRNA expression in the mature B cell line CH12, but not in the LPS-sensitive pre-B cell line, 70Z/3. The activator LPS does not affect EP1 nor EP mRNA expression. Treatment with dbcAMP, an analog of cAMP, mimics PGE-induced growth inhibition indicating that Gs-coupled EP2 and/or EP4 receptors mediate this inhibitory signal. Indeed, EP2 agonists mimic PGE2-induced growth inhibition unlike IP, EP1 and EP3-selective agonists. These data indicate that EP2 receptors are sufficient for mediating PGE-induced growth inhibition of susceptible B lineage cells.

Original languageEnglish (US)
Pages (from-to)33-45
Number of pages13
JournalMolecular Immunology
Volume33
Issue number1
DOIs
StatePublished - Jan 1996

Fingerprint

Prostaglandin E Receptors
B-Lymphocytes
Prostaglandins E
Cell Line
Dinoprostone
Lymphoma
Growth
Messenger RNA
B-Lymphoid Precursor Cells
Receptors, Prostaglandin E, EP3 Subtype
Receptors, Prostaglandin E, EP4 Subtype
Dimercaprol
Reverse Transcriptase Polymerase Chain Reaction
DNA Sequence Analysis
Northern Blotting
Up-Regulation

Keywords

  • B lymphocyte
  • B lymphoma
  • EP
  • EP
  • EP
  • EP
  • Growth inhibition
  • LPS
  • Mouse
  • Myeloma
  • PGE
  • Prostaglandin

ASJC Scopus subject areas

  • Immunology
  • Molecular Biology

Cite this

A molecular analysis of PGE receptor (EP) expression on normal and transformed B lymphocytes : Coexpression of EP1, EP2, EP and EP4. / Fedyk, Eric R.; Ripper, John M.; Brown, Deborah M.; Phipps, Richard P.

In: Molecular Immunology, Vol. 33, No. 1, 01.1996, p. 33-45.

Research output: Contribution to journalArticle

@article{f6aedd03bac6404a81c0e40ad469163d,
title = "A molecular analysis of PGE receptor (EP) expression on normal and transformed B lymphocytes: Coexpression of EP1, EP2, EP3β and EP4",
abstract = "The E-series prostaglandins (PGEs) are complex lipid regulators of B lymphocyte function. They inhibit the growth of certain B lymphoma lines. We report that heterogeneity with respect to PGE-induced growth inhibition correlates with the maturation state of the B cell lines. Specifically, the pre-B cell line 70Z/3 and the immature lymphoma CH31 are extremely sensitive to PGE2. To a lesser degree, other immature lymphomas (CH33, ECH408.1 and WEHI-231) are sensitive to PGE2. More mature lymphomas (BAL-17, CH12 and CH27) and fully differentiated myelomas (J558 and MOPC-315) are insensitive to PGE2. It is unknown what subtype of PGE receptor(s) (EPs) are expressed by B lymphocytes. It is also unknown if modulation of EP receptor expression could account for the differences in the sensitivity of these B cell lines to PGE2. To investigate these issues, reverse transcriptase polymerase chain reaction, Northern blot and DNA sequencing analyses were employed to obtain a definitive EP receptor subtype profile for these B cell lines, and for normal splenic B lymphocytes. Both normal and transformed B lymphocytes express mRNA encoding EP1, EP3β and EP4 subtypes of PGE receptors. The B lineage cells do not express EP3α nor EP3γ mRNA. The B cell lines are clonal, indicating that EP1, EP3β and EP4 mRNA are coexpressed. Surprisingly, quantitative differences in basal EP1, EP3β and EP4 expression were not observed between B cell lines despite their differing susceptibilities to PGE-induced growth inhibition. Conversely, the polyclonal activator LPS selectively upregulates EP4 mRNA expression in the mature B cell line CH12, but not in the LPS-sensitive pre-B cell line, 70Z/3. The activator LPS does not affect EP1 nor EP3β mRNA expression. Treatment with dbcAMP, an analog of cAMP, mimics PGE-induced growth inhibition indicating that Gs-coupled EP2 and/or EP4 receptors mediate this inhibitory signal. Indeed, EP2 agonists mimic PGE2-induced growth inhibition unlike IP, EP1 and EP3-selective agonists. These data indicate that EP2 receptors are sufficient for mediating PGE-induced growth inhibition of susceptible B lineage cells.",
keywords = "B lymphocyte, B lymphoma, EP, EP, EP, EP, Growth inhibition, LPS, Mouse, Myeloma, PGE, Prostaglandin",
author = "Fedyk, {Eric R.} and Ripper, {John M.} and Brown, {Deborah M.} and Phipps, {Richard P.}",
year = "1996",
month = "1",
doi = "10.1016/0161-5890(95)00130-1",
language = "English (US)",
volume = "33",
pages = "33--45",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - A molecular analysis of PGE receptor (EP) expression on normal and transformed B lymphocytes

T2 - Coexpression of EP1, EP2, EP3β and EP4

AU - Fedyk, Eric R.

AU - Ripper, John M.

AU - Brown, Deborah M.

AU - Phipps, Richard P.

PY - 1996/1

Y1 - 1996/1

N2 - The E-series prostaglandins (PGEs) are complex lipid regulators of B lymphocyte function. They inhibit the growth of certain B lymphoma lines. We report that heterogeneity with respect to PGE-induced growth inhibition correlates with the maturation state of the B cell lines. Specifically, the pre-B cell line 70Z/3 and the immature lymphoma CH31 are extremely sensitive to PGE2. To a lesser degree, other immature lymphomas (CH33, ECH408.1 and WEHI-231) are sensitive to PGE2. More mature lymphomas (BAL-17, CH12 and CH27) and fully differentiated myelomas (J558 and MOPC-315) are insensitive to PGE2. It is unknown what subtype of PGE receptor(s) (EPs) are expressed by B lymphocytes. It is also unknown if modulation of EP receptor expression could account for the differences in the sensitivity of these B cell lines to PGE2. To investigate these issues, reverse transcriptase polymerase chain reaction, Northern blot and DNA sequencing analyses were employed to obtain a definitive EP receptor subtype profile for these B cell lines, and for normal splenic B lymphocytes. Both normal and transformed B lymphocytes express mRNA encoding EP1, EP3β and EP4 subtypes of PGE receptors. The B lineage cells do not express EP3α nor EP3γ mRNA. The B cell lines are clonal, indicating that EP1, EP3β and EP4 mRNA are coexpressed. Surprisingly, quantitative differences in basal EP1, EP3β and EP4 expression were not observed between B cell lines despite their differing susceptibilities to PGE-induced growth inhibition. Conversely, the polyclonal activator LPS selectively upregulates EP4 mRNA expression in the mature B cell line CH12, but not in the LPS-sensitive pre-B cell line, 70Z/3. The activator LPS does not affect EP1 nor EP3β mRNA expression. Treatment with dbcAMP, an analog of cAMP, mimics PGE-induced growth inhibition indicating that Gs-coupled EP2 and/or EP4 receptors mediate this inhibitory signal. Indeed, EP2 agonists mimic PGE2-induced growth inhibition unlike IP, EP1 and EP3-selective agonists. These data indicate that EP2 receptors are sufficient for mediating PGE-induced growth inhibition of susceptible B lineage cells.

AB - The E-series prostaglandins (PGEs) are complex lipid regulators of B lymphocyte function. They inhibit the growth of certain B lymphoma lines. We report that heterogeneity with respect to PGE-induced growth inhibition correlates with the maturation state of the B cell lines. Specifically, the pre-B cell line 70Z/3 and the immature lymphoma CH31 are extremely sensitive to PGE2. To a lesser degree, other immature lymphomas (CH33, ECH408.1 and WEHI-231) are sensitive to PGE2. More mature lymphomas (BAL-17, CH12 and CH27) and fully differentiated myelomas (J558 and MOPC-315) are insensitive to PGE2. It is unknown what subtype of PGE receptor(s) (EPs) are expressed by B lymphocytes. It is also unknown if modulation of EP receptor expression could account for the differences in the sensitivity of these B cell lines to PGE2. To investigate these issues, reverse transcriptase polymerase chain reaction, Northern blot and DNA sequencing analyses were employed to obtain a definitive EP receptor subtype profile for these B cell lines, and for normal splenic B lymphocytes. Both normal and transformed B lymphocytes express mRNA encoding EP1, EP3β and EP4 subtypes of PGE receptors. The B lineage cells do not express EP3α nor EP3γ mRNA. The B cell lines are clonal, indicating that EP1, EP3β and EP4 mRNA are coexpressed. Surprisingly, quantitative differences in basal EP1, EP3β and EP4 expression were not observed between B cell lines despite their differing susceptibilities to PGE-induced growth inhibition. Conversely, the polyclonal activator LPS selectively upregulates EP4 mRNA expression in the mature B cell line CH12, but not in the LPS-sensitive pre-B cell line, 70Z/3. The activator LPS does not affect EP1 nor EP3β mRNA expression. Treatment with dbcAMP, an analog of cAMP, mimics PGE-induced growth inhibition indicating that Gs-coupled EP2 and/or EP4 receptors mediate this inhibitory signal. Indeed, EP2 agonists mimic PGE2-induced growth inhibition unlike IP, EP1 and EP3-selective agonists. These data indicate that EP2 receptors are sufficient for mediating PGE-induced growth inhibition of susceptible B lineage cells.

KW - B lymphocyte

KW - B lymphoma

KW - EP

KW - EP

KW - EP

KW - EP

KW - Growth inhibition

KW - LPS

KW - Mouse

KW - Myeloma

KW - PGE

KW - Prostaglandin

UR - http://www.scopus.com/inward/record.url?scp=0029944538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029944538&partnerID=8YFLogxK

U2 - 10.1016/0161-5890(95)00130-1

DO - 10.1016/0161-5890(95)00130-1

M3 - Article

C2 - 8604222

AN - SCOPUS:0029944538

VL - 33

SP - 33

EP - 45

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

IS - 1

ER -